A safety review of CBD as an anti-inflammatory agent | Research

The takeaway

CBD appears generally well-tolerated with anti-inflammatory potential, but safety data remains limited, especially for long-term use and drug interactions.

CBD consumers, healthcare providers advising on CBD use, and researchers studying cannabinoid safety profiles.

CBD safety data largely drawn from epilepsy trials, not consumer-grade products

What the researchers found

CBD has demonstrated anti-inflammatory properties across multiple preclinical and clinical contexts, with a safety profile that includes possible liver enzyme effects, drug interactions, and gastrointestinal symptoms at higher doses.

Why it matters

CBD products are widely available and marketed for inflammation, but consumers and clinicians need clearer information about what safety data actually exists versus what is simply assumed.

The numbers in context

The review covers multiple CBD administration modes and discusses safety signals including hepatotoxicity risk at high doses and interactions with cytochrome P450 enzymes.

How the study worked

Narrative review of published literature on CBD pharmacology, anti-inflammatory mechanisms, and safety data. Includes discussion of patents and various administration routes.

What this study cannot tell us

Narrative review without systematic methodology. Does not include quantitative synthesis of safety data. Relies heavily on preclinical evidence. Published safety data skews toward pharmaceutical-grade CBD, not consumer products.

How to read the evidence

Narrative review without systematic search methodology. Provides useful overview but limited by lack of rigorous evidence synthesis.

When this study was published

Published 2022.

The bigger picture

The gap between CBD market growth and rigorous safety research continues to widen. Most safety data comes from epilepsy trials using pharmaceutical-grade CBD at specific doses, which may not reflect the diverse products consumers actually use.

Questions still open

What are the long-term safety outcomes for daily CBD use at common consumer doses? How do impurities and inconsistent potency in commercial CBD products affect the safety profile?

Common questions

Is CBD safe to use?

CBD is generally well-tolerated in most people. However, it can cause side effects including fatigue, diarrhea, and changes in appetite. At higher doses, liver enzyme elevations have been reported. CBD also interacts with several medications through cytochrome P450 pathways.

Can CBD reduce inflammation?

Preclinical research shows CBD has anti-inflammatory properties through multiple mechanisms. Clinical evidence is more limited, with most human data coming from studies on specific conditions like epilepsy rather than inflammation directly.

Read the original research

Current Cannabidiol Safety: A Review.

Current drug safety, 18(4), 465-473

View on PubMed ↗Publisher’s paper ↗

Citation

Singh, Chander; Rao, Komal; Yadav, Nikita; Vashist, Yogesh; Chugh, Palak; Bansal, Nidhi; Minocha, Neha. (2023). Current Cannabidiol Safety: A Review.. Current drug safety, 18(4), 465-473. https://doi.org/10.2174/1574886317666220902100511